Halozyme Therapeutics (HALO) EV to EBITDA (2017 - 2026)
Halozyme Therapeutics' EV to EBITDA was 12.21 in Q2 2026, up 67.6% from 7.29 a year earlier and up 2.0% from the prior quarter.
Powered by 
Analysis
Halozyme Therapeutics (HALO) EV to EBITDA (2017 - 2026) Analysis & Trends
On a trailing twelve-month basis, Halozyme Therapeutics' EV to EBITDA was 10.58 through Jun 30, 2026, up 127.1% year-over-year; for FY2025, it came in at 13.97, up 67.1% from FY2024.
- In earlier years, EV to EBITDA was 8.36 in FY2024 (-18.8%), 10.30 in FY2023 (-55.4%), 23.10 in FY2022 (+34.1%) and 17.22 in FY2021 (-53.5%).
- Quarterly EV to EBITDA has moved between 7.29 (Q2 2025) and 23.10 (Q4 2022) over five years.
- Compared with a year earlier, EV to EBITDA has increased for three straight quarters, with growth averaging 9.0% over the last eight quarters.
- The best year-over-year quarter for EV to EBITDA over five years was Q2 2026 (growth of 67.6%); the worst was Q3 2021 (a decline of 80.5%).
- Per Business Quant data, HALO's EV to EBITDA in the three quarters before Q2 2026 was 11.97 (Q1 2026), 13.97 (Q4 2025) and 9.66 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn |
| 10 | Halozyme Therapeutics | 12.59 Bn | 11.20 Bn | 401.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 12.21 |
| Mar 31, 2026 | 11.97 |
| Dec 31, 2025 | 13.97 |
| Sep 30, 2025 | 9.66 |
| Jun 30, 2025 | 7.29 |
| Mar 31, 2025 | 10.47 |
| Dec 31, 2024 | 8.36 |
| Sep 30, 2024 | 11.84 |
| Jun 30, 2024 | 12.53 |
| Mar 31, 2024 | 10.15 |
| Dec 31, 2023 | 10.30 |
| Sep 30, 2023 | 11.93 |
| Jun 30, 2023 | 11.49 |
| Mar 31, 2023 | 15.09 |
| Dec 31, 2022 | 23.10 |
| Sep 30, 2022 | 17.35 |
| Jun 30, 2022 | 22.79 |
| Mar 31, 2022 | 15.51 |
| Dec 31, 2021 | 17.22 |
| Sep 30, 2021 | 16.39 |
API Access
Halozyme Therapeutics EV to EBITDA API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=HALO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ev-to-ebitda", "ticker": "HALO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ev-to-ebitda&ticker=HALO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();